MedTrace Logo

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

NCT00910728 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2017-04-24

Study results available
· View outcomes & findings →

Summary

This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD1480 in the body over a period of time and will indicate whether the drug has a therapeutic effect on myeloproliferative diseases.

Conditions

  • Primary Myelofibrosis (PMF)
  • Post-Polycythaemia Vera
  • Essential Thrombocythaemia Myelofibrosis

Interventions

DRUG

AZD1480

Oral capsule 2.5 mg, 10 mg and 40 mg

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER

  • New York City Hoffman Center

    collaborator UNKNOWN

  • Gustave Roussy, Cancer Campus, Grand Paris

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Srdan Verstovsek, MD · MDACC

  • Ronald Hoffman, MD · Mt. Sinai

  • Vincent Ribrag, MD · Gustave Roussy, Cancer Campus, Grand Paris

  • Becker Hewes, MD · AstraZeneca

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-03-31
Completion
2014-08-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00910728 on ClinicalTrials.gov